NASDAQ · Health care

Dare Bioscience, Inc. (DARE)

It posted a net loss of $11M. In fiscal 2025 capital spending exceeded operating cash flow by $10.3M. At June 30, 2026 it held $12.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$0.78

+4.73% on the day · September 25, 2026

52-week range $0.69 to $3.78

Market cap

$11.9M

What Dare Bioscience, Inc. does

Dare Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DARE.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1M	-$13.6M	-$13.4M	-$1.20	-$10.3M
2024	$9.8K	-$23.5M	-$4.1M	-$0.48	$4.9M
2023	$2.8M	-$30.9M	-$30.2M	-$4.15	-$39.5M
2022	$10M	-$31.4M	-$30.9M	-$4.39	-$18.2M
2021	$0	-$39.1M	-$38.7M	-$7.47	-$28.8M
2020	n/a	-$27.4M	-$27.4M	-$10.79	-$25.3M

Next report expected around October 22, 2026.

Estimated from its filing rhythm: about 70 days after its last report of August 13, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where DARE ranks in Health care

Revenue$1M

#568 of 646 in Health care · Bottom 12%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Dare Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 23, 2026
Preliminary proxy statement PRE 14A
September 11, 2026
Bylaws or fiscal year changed 8-K
September 9, 2026
Investor disclosure 8-K
September 4, 2026
Securities offering prospectus 424B3
August 28, 2026
Passive stake (5% or more) SCHEDULE 13G
August 26, 2026
IPO registration S-1
August 24, 2026
Passive stake (5% or more) SCHEDULE 13G
August 19, 2026
Form 253G2 filing 253G2
August 17, 2026
Material agreement 8-K
August 17, 2026
Securities offering prospectus 424B5

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 2, 2026. Insider transactions on SEC

Insider trades

What the people running Dare Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
June 30, 2026	Steele Robin JoanDirector	Received as pay	26,540	-	-	Form 4
June 30, 2026	Rastetter William HDirector	Received as pay	38,862	-	-	Form 4
June 30, 2026	Matz Gregory WDirector	Received as pay	30,805	-	-	Form 4
June 30, 2026	Kelley Susan L.Director	Received as pay	23,696	-	-	Form 4
June 30, 2026	Grossman Jessica D.Director	Received as pay	26,066	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns DARE

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
L1 Capital Global Opportunities Master Fund, Ltd.13G, passive	9.99%	2,028,885	August 24, 2026
Lind Global Fund III LP13G, passive with 2 related filers	5.65%	1,094,890	August 28, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 167,385 shares in total, about $129.8K at the last price.

Holder	Shares	As of
Steele Robin JoanDirector	47,055	June 30, 2026
Rastetter William HDirector	39,721	June 30, 2026
Matz Gregory WDirector	30,847	June 30, 2026
Grossman Jessica D.Director	26,066	June 30, 2026
Kelley Susan L.Director	23,696	June 30, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about DARE

What does Dare Bioscience, Inc. do?

Dare Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DARE.

Is Dare Bioscience, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11M.

When did Dare Bioscience, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from September 23, 2026.

Similar companies

Compare DARE with

Compare DARE with any company

Follow DARE

Get an email when Dare Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow DARE: get an email when it files

Where the numbers come from

Financial figures are the values Dare Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.